Salish Stories Group

The Dominance of Drug-Eluting Stents (DES) in the US PCI Market

The US Percutaneous Coronary Intervention (PCI) Market is fundamentally defined by the overwhelming dominance of a single product segment: Drug-Eluting Stents (DES). These advanced devices have a near-monopoly on the market, capturing an impressive 82.3% share in 2024. The widespread adoption of DES is a direct result of their superior clinical efficacy, which has revolutionized the treatment of coronary artery disease. By slowly releasing a drug to prevent the re-narrowing of the artery (restenosis), DES significantly improve long-term patient outcomes compared to older bare-metal stents (BMS). This clinical superiority has made DES the standard of care in the vast majority of PCI procedures. The fierce competition among manufacturers like Abbott, Boston Scientific, and Medtronic to develop the next generation of thinner, more flexible, and more effective DES has created a highly innovative environment, driving continuous advancements in the field.

Link: Understand the crucial role of Drug-Eluting Stents in the market

FAQs

• Why are Drug-Eluting Stents so popular? DES are preferred because they release medication that prevents the artery from re-narrowing, leading to better long-term outcomes for patients.

• Do bare-metal stents still have a role? While their market share is much smaller, bare-metal stents are still used in specific clinical situations where DES are not indicated, such as for patients who cannot take certain medications.